Authors are advised to read these guidelines carefully before submitting a manuscript to JCollBiomed. Manuscripts that do not comply with the journal’s scope, ethical policies, or formatting requirements may be returned to the authors before entering the peer-review process.

1. General Requirements

Submitted manuscripts must:

• Fall within the Focus and Scope of JCollBiomed;
• Be original and not previously published, except as a preprint, conference abstract, thesis, or dissertation that has been transparently disclosed;
• Not be under consideration by another journal;
• Have been read and approved by all listed authors;
• Include all individuals who meet recognized authorship criteria;
• Comply with applicable ethical requirements for research involving humans, animals, biological materials, and identifiable data;
• Be written in clear and academically appropriate English;
• Present accurate, transparent, and reproducible methods and results; and
• Disclose funding, competing interests, data availability, and the use of artificial intelligence (AI) tools.

All manuscripts will undergo an initial editorial assessment and plagiarism screening before being considered for peer review.

2. Types of Manuscripts

JCollBiomed accepts the following manuscript types:

Original Research Article

Reports original laboratory, experimental, translational, clinical, or population-based biomedical research.

• Maximum main-text length: 6,000 words;
• Structured abstract: maximum 300 words;
• Keywords: 3–6;
• References: preferably no more than 50; and
• Combined tables and figures: preferably no more than 8.

Systematic Review and Meta-analysis

Presents a methodologically rigorous synthesis of available evidence. Authors should follow PRISMA and, when applicable, register the protocol in PROSPERO, OSF, or another recognized repository.

• Maximum main-text length: 7,000 words;
• Structured abstract: maximum 300 words;
• Keywords: 3–6;
• References: according to the requirements of the review; and
• A completed PRISMA checklist and flow diagram must be submitted.

Scoping Review

Maps the available evidence, concepts, research gaps, or methodological characteristics of a defined topic. Authors should follow PRISMA-ScR.

• Maximum main-text length: 7,000 words;
• Structured abstract: maximum 300 words;
• Keywords: 3–6; and
• A completed PRISMA-ScR checklist must be submitted.

Critical Narrative Review

Provides a focused, analytical, and evidence-based synthesis of an important biomedical topic. A narrative review should critically evaluate the literature rather than merely summarize published studies. The literature search approach and study-selection strategy must be described transparently.

• Maximum main-text length: 6,000 words;
• Abstract: maximum 250 words;
• Keywords: 3–6; and
• References: preferably no more than 100.

Brief Research Report

Presents scientifically valid preliminary findings, pilot studies, replication studies, or concise original investigations.

• Maximum main-text length: 3,000 words;
• Structured abstract: maximum 200 words;
• References: preferably no more than 30; and
• Combined tables and figures: maximum 4.

Methodological or Technical Paper

Describes the development, validation, optimization, or application of a biomedical method, instrument, laboratory procedure, computational approach, or research technology.

• Maximum main-text length: 5,000 words;
• Structured abstract: maximum 250 words;
• Keywords: 3–6; and
• Authors must provide sufficient information to allow validation or replication.

Letter to the Editor

Provides a scholarly comment on an article published in JCollBiomed or discusses a timely issue relevant to biomedical science.

• Maximum length: 1,000 words;
• Maximum references: 10;
• Maximum number of tables or figures: 1; and
• No abstract is required.

Word limits exclude the abstract, references, tables, figure legends, and supplementary materials.

3. Submission Files

Authors should prepare and upload the following files:

1. Cover letter;
2. Title page;
3. Blinded main manuscript;
4. Figures, when submitted separately;
5. Supplementary materials, when applicable;
6. Reporting-guideline checklist, when applicable; and
7. Ethical approval or other supporting documentation when requested by the editors.

Files should be submitted in Microsoft Word format (.doc or .docx). Tables must remain editable and should not be submitted as images.

4. Cover Letter

The cover letter should include:

• The complete manuscript title;
• The manuscript type;
• A concise explanation of the novelty and scientific contribution of the study;
• A statement confirming that the manuscript is original and is not under consideration elsewhere;
• Confirmation that all authors have approved the submitted version;
• Disclosure of related manuscripts, preprints, conference abstracts, or overlapping publications;
• Disclosure of potential conflicts of interest; and
• The name and contact information of the corresponding author.

Authors may suggest potential reviewers with appropriate expertise. Suggested reviewers must not have recent collaborations, institutional relationships, supervisory relationships, or other conflicts of interest with the authors. The editor is not obligated to use the suggested reviewers.

5. Title Page

The title page must be submitted separately and should contain:

• A concise and informative title, preferably not exceeding 20 words;
• Full names of all authors without academic titles;
• The institutional affiliation of each author, including department, institution, city, and country;
• ORCID iDs of all authors, where available;
• The full name, institutional address, and email address of the corresponding author;
• A short running title of no more than 50 characters;
• Main-text word count;
• Number of tables, figures, and supplementary files;
• Author-contribution statement;
• Funding information;
• Declaration of competing interests; and
• Acknowledgments, when applicable.

The order and spelling of author names should be checked carefully before submission.

6. Blinded Main Manuscript

JCollBiomed applies anonymized peer review. Therefore, the main manuscript must not contain:

• Author names or academic titles;
• Institutional affiliations;
• Email addresses or ORCID iDs;
• Acknowledgments that reveal author identities;
• Institution-identifying information that is not scientifically necessary; or
• File metadata that reveals the authors’ identities.

Authors should replace identifiable information with neutral descriptions during peer review, for example, “the study institution” or “[institution name removed for peer review].” Complete information may be restored after acceptance.

7. Manuscript Formatting

Manuscripts should use:

• A4 page size;
• Times New Roman, 12-point font;
• Double-line spacing;
• Margins of at least 2.5 cm;
• Continuous page and line numbering;
• Left-aligned text;
• Standard scientific terminology; and
• International System of Units (SI).

Abbreviations should be defined at first mention and used consistently. Excessive or unnecessary abbreviations should be avoided.

Generic names should be used for drugs and chemical substances. Proprietary names may be stated in parentheses when scientifically necessary. Genus and species names must be italicized, with the full scientific name provided at first mention.

8. Structure of an Original Research Article

Original research manuscripts should be arranged as follows:

Title

The title should accurately reflect the principal topic, population, exposure or intervention, and study design, when appropriate. Avoid unnecessary abbreviations and overly broad claims.

Abstract

The abstract should be structured using the following headings:

• Background;
• Objective;
• Methods;
• Results; and
• Conclusion.

The abstract must include the principal numerical findings and should not contain references, undefined abbreviations, or claims unsupported by the results.

Keywords

Provide three to six keywords. Authors are encouraged to select terms from the National Library of Medicine’s Medical Subject Headings (MeSH).

Introduction

The Introduction should:

• Explain the scientific background and significance of the problem;
• Summarize the relevant evidence;
• Identify the specific knowledge gap; and
• Clearly state the research objective or hypothesis.

The Introduction should not contain an extensive literature review or report the study results.

Methods

The Methods section should provide sufficient detail to allow evaluation and replication. It should include, as applicable:

• Study design and setting;
• Study period;
• Participant, sample, or experimental-material characteristics;
• Eligibility criteria;
• Sampling method and sample-size calculation;
• Variables and operational definitions;
• Intervention, exposure, or experimental procedures;
• Laboratory methods, instruments, reagents, and manufacturers;
• Outcome measurements;
• Strategies for controlling bias and confounding;
• Statistical analysis;
• Ethical approval and informed consent; and
• Clinical trial registration.

For cell-line research, authors should report the source, authentication method, and mycoplasma-contamination status, when relevant. For molecular studies, primer sequences, antibodies, reagents, databases, and analytical pipelines should be reported in sufficient detail to facilitate reproducibility.

Results

Results should be presented clearly and objectively without unnecessary interpretation. Authors should report:

• Participant or sample flow;
• Baseline or descriptive characteristics;
• Primary and secondary findings;
• Effect estimates with confidence intervals, where appropriate;
• Exact p-values, except when p < 0.001;
• Missing data and excluded observations; and
• Relevant negative or non-significant findings.

Data should not be unnecessarily duplicated between the text, tables, and figures.

Discussion

The Discussion should:

• Summarize the principal findings without repeating the Results section;
• Explain the biological, clinical, or translational significance of the findings;
• Critically compare the results with previous evidence;
• Discuss plausible mechanisms;
• Identify the study’s strengths and limitations;
• Avoid causal claims when the study design demonstrates only an association;
• Explain implications for research, practice, or policy; and
• Provide realistic recommendations for future research.

Conclusion

The Conclusion must be concise, directly supported by the findings, and consistent with the study design. New data, unsupported generalizations, and exaggerated clinical implications should not be introduced.

9. Reporting Guidelines

Authors should follow the appropriate reporting guideline for their study design. Relevant guidelines can be identified through the EQUATOR Network, including:

• CONSORT for randomized controlled trials;
• STROBE for observational studies;
• PRISMA for systematic reviews and meta-analyses;
• PRISMA-ScR for scoping reviews;
• STARD for diagnostic-accuracy studies;
• ARRIVE 2.0 for animal experiments;
• TRIPOD for prediction-model studies;
• CHEERS for health-economic evaluations;
• SQUIRE for quality-improvement studies; and
• SPIRIT for clinical-trial protocols.

The applicable checklist and flow diagram should be uploaded as supplementary files when required.

10. Statistical Reporting

Statistical methods should be described in sufficient detail to permit evaluation and, where appropriate, replication. Authors should:

• Identify the statistical software and version;
• Explain the sample-size calculation or justification;
• Describe how assumptions for statistical tests were evaluated;
• Report effect sizes and confidence intervals whenever appropriate;
• Distinguish between pre-specified and exploratory analyses;
• Explain the handling of missing data, outliers, repeated measurements, and multiple comparisons;
• Avoid interpreting statistical significance as evidence of clinical importance;
• Report exact p-values to three decimal places, except for values below 0.001; and
• Avoid reporting a p-value as p = 0.000.

Statistical analyses should be appropriate to the study design, distribution of the data, level of measurement, and research objectives.

11. Tables and Figures

Tables and figures must:

• Be numbered consecutively according to their first citation in the text;
• Have concise and self-explanatory titles or legends;
• Define all abbreviations and symbols;
• Include units of measurement;
• Avoid duplicating information already presented in the text; and
• Clearly identify statistical comparisons and significance indicators.

Tables must be created using the table function in a word-processing program.

Figures should be submitted in JPEG, PNG, or TIFF format with sufficient resolution:

• Minimum 300 dpi for photographs and colour images;
• Minimum 600 dpi for line drawings; and
• Higher resolution may be requested when necessary.

Image adjustments must be applied consistently to the entire image. Selective enhancement, deletion, movement, or concealment of image features is prohibited. Authors may be asked to provide original, uncropped, and unprocessed image files.

Authors are responsible for obtaining permission to reproduce copyrighted tables, figures, questionnaires, or other materials.

12. References

JCollBiomed uses the Vancouver referencing style.

References should:

• Be numbered consecutively according to the order of first citation;
• Be cited in the text using Arabic numbers in square brackets, for example, [1] and [2–4];
• Use abbreviated journal titles based on the NLM Catalog;
• Include a DOI whenever available;
• Prefer primary, current, and peer-reviewed sources;
• Avoid excessive reliance on non-peer-reviewed websites, textbooks, or secondary citations; and
• Be checked carefully for accuracy.

Reference-management software such as Zotero, Mendeley, or EndNote is recommended.

Journal article example:

Yuliasih Y, Rahmawati LD, Putri RM. Th17/Treg ratio and disease activity in systemic lupus erythematosus. Caspian J Intern Med. 2019;10(1):65–72. doi:10.22088/cjim.10.1.65.

Book example:

Murray RK, Bender DA, Botham KM, Kennelly PJ, Rodwell VW, Weil PA. Harper’s illustrated biochemistry. 31st ed. New York: McGraw-Hill Education; 2018.

Website example:

World Health Organization. Noncommunicable diseases [Internet]. Geneva: World Health Organization; 2025 [cited 2026 Aug 13].

13. Ethical Approval and Informed Consent

Studies involving human participants, identifiable human data, or human biological materials must include:

• The name of the approving ethics committee;
• The ethical approval number;
• The date of approval, when required;
• A statement regarding informed consent; and
• An explanation of any ethics or consent waiver.

Research must comply with applicable regulations and the current Declaration of Helsinki.

Animal research must identify the responsible animal ethics committee and approval number and should follow the ARRIVE Guidelines 2.0.

14. Required Declarations

The following statements must be placed after the Conclusion and before the References:

Ethics Approval and Consent to Participate

Provide the name of the ethics committee, approval number, and informed-consent statement. If not applicable, state:

Ethics approval and consent to participate: Not applicable.

Consent for Publication

State whether consent for publication was obtained, particularly when identifiable participant information is presented.

Data Availability

Identify where and how the data supporting the findings can be accessed. If the data cannot be publicly shared, explain the applicable ethical, privacy, or legal restrictions.

Competing Interests

All authors must disclose relevant competing interests. If none exist, state:

The authors declare that they have no competing interests.

Funding

Identify the funder and grant number and describe the funder’s role. If no external funding was received, state:

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Author Contributions

Author contributions should be described using the CRediT taxonomy where possible, including conceptualization, methodology, investigation, data curation, formal analysis, writing, supervision, and funding acquisition.

Acknowledgments

Acknowledge individuals or institutions that contributed to the work but did not meet the authorship criteria. Permission should be obtained from individuals named in this section.

Artificial Intelligence Disclosure

Authors must disclose the use of generative AI or AI-assisted technologies, including the tool, version when available, purpose, and manner of use. AI tools cannot be listed as authors. Authors remain responsible for the accuracy, originality, confidentiality, and integrity of the manuscript, consistent with current ICMJE guidance.

15. Revised Manuscripts

When submitting a revision, authors must provide:

• A clean revised manuscript;
• A version showing tracked or highlighted changes; and
• A detailed point-by-point response to every reviewer and editor comment.

Each response should indicate where the corresponding revision appears in the manuscript. When authors disagree with a recommendation, they should provide a respectful and evidence-based explanation.

16. Proofreading and Publication

Following acceptance, the corresponding author will receive the article proof for final checking. Only minor corrections involving spelling, formatting, affiliations, or factual production errors may be made at this stage. Substantial changes to data, authorship, results, or conclusions require editorial approval.

The corresponding author is responsible for returning the corrected proof within the specified period and ensuring that all authors have approved the final version.